Overview

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2018-10-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465

Phase:

Phase 1

Details

Lead Sponsor:

Shire

Treatments:

Amphetamine